ArticleClinical journal of the American Society of Nephrology : CJASN2019
Etiology and Outcomes of Thrombotic Microangiopathies.
Article in Clinical journal of the American Society of Nephrology : CJASN, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 92 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
French National Cohort MATRIX "Renal and Systemic Thrombotic Microangiopathy"
Prevalence of Hemolytic Uremic Syndrome (HUS) in Pediatrics at Assiut University Children's Hospital: A Prospective Study
Who cites it
92 citing papers in PubMed, 2 syntheses or guidelines pooled it, 157 citations in OpenAlex.
- Kidney and pregnancy outcomes in pregnancy-associated atypical hemolytic uremic syndrome: A systematic review and meta-analysis.Medicine · 2025Pooled it
- Recommendations for diagnosis and treatment of Atypical Hemolytic Uremic Syndrome (aHUS): an expert consensus statement from the Rare Diseases Committee of the Brazilian Society of Nephrology (COMDORA-SBN).Jornal brasileiro de nefrologiaGuideline
- Drug-Induced Thrombotic Microangiopathy in Patients with Cancer : A Clinicopathologic Series.Kidney360 · 2026Article
- Revisiting clinical scoring tools for the diagnosis of thrombotic thrombocytopenic purpura (TTP).Journal of thrombosis and thrombolysis · 2026Review
- Causes and outcomes of pediatric thrombotic microangiopathy.Research and practice in thrombosis and haemostasis · 2026Article
- Analysis of causes and outcomes of principal secondary thrombotic microangiopathy: a 9-year cohort study from a tertiary pediatric center in China.Research and practice in thrombosis and haemostasis · 2026Article
- Gemcitabine-sirolimus synergy associated thrombotic microangiopathy in a renal transplant recipient with mesenteric leiomyosarcoma: A case report.World journal of transplantation · 2026Article
- A case of membranous proliferative glomerulonephritis-type IgA nephropathy modified by nintedanib.CEN case reports · 2026Article
- Article
- Hypertensive crisis in the critically ill.Annals of intensive care · 2026Review
- Cytomegalovirus viremia associated with systemic thrombotic microangiopathy after kidney transplantation: a case report.Frontiers in medicine · 2026Article
- Secondary thrombotic microangiopathy following lung transplantation: a multicenter European cohort study.Transplant international : official journal of the European Society for Organ Transplantation · 2026Article
- Comparative Analysis of Clinicopathological Features and Outcomes Between Kidney-Limited and Systemic Thrombotic Microangiopathy: A Study Based on a Semiquantitative Pathological Scoring System.International journal of nephrology and renovascular disease · 2026Article
- Update in the diagnosis of complement-mediated thrombotic microangiopathy/atypical hemolytic uremic syndrome.Hematology. American Society of Hematology. Education Program · 2025Review
- Renal survival and improvement in younger malignant hypertension patients with thrombotic microangiopathy.Renal failure · 2025Article
- Histologic Features Associated with Kidney Survival in Scleroderma Renal Crisis.Journal of the American Society of Nephrology : JASN · 2025Article
- Complement activation in secondary thrombotic microangiopathies.Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association · 2025Review
- Comprehensive genetic analysis and genotype-phenotype correlations in pediatric patients with atypical hemolytic uremic syndrome.Pediatric nephrology (Berlin, Germany) · 2025Article
- The impact of the COVID-19 pandemic on incidence and clinical presentation of thrombotic microangiopathies: data from a laboratory centralizing ADAMTS-13 testing in Quebec.Orphanet journal of rare diseases · 2025Article
- Clinical Manifestations, Treatment Characteristics, and Clinical Outcomes in Patients with Immune Thrombotic Thrombocytopenic Purpura (iTTP) in a Real-World Setting: An Interim Analysis of the Turkish iTTP RegistryTurkish journal of haematology : official journal of Turkish Society of Haematology · 2025Observational
32 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
21 authors at 5 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND AND
objectivesThrombotic microangiopathies constitute a diagnostic and therapeutic challenge. Secondary thrombotic microangiopathies are less characterized than primary thrombotic microangiopathies (thrombotic thrombocytopenic purpura and atypical hemolytic and uremic syndrome). The relative frequencies and outcomes of secondary and primary thrombotic microangiopathies are unknown. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: We conducted a retrospective study in a four-hospital institution in 564 consecutive patients with adjudicated thrombotic microangiopathies during the 2009-2016 period. We estimated the incidence of primary and secondary thrombotic microangiopathies, thrombotic microangiopathy causes, and major outcomes during hospitalization (death, dialysis, major cardiovascular events [acute coronary syndrome and/or acute heart failure], and neurologic complications [stroke, cognitive impairment, or epilepsy]).
resultsWe identified primary thrombotic microangiopathies in 33 of 564 patients (6%; thrombotic thrombocytopenic purpura: 18 of 564 [3%]; atypical hemolytic and uremic syndrome: 18 of 564 [3%]). Secondary thrombotic microangiopathies were found in 531 of 564 patients (94%). A cause was identified in 500 of 564 (94%): pregnancy (35%; 11 of 1000 pregnancies), malignancies (19%), infections (33%), drugs (26%), transplantations (17%), autoimmune diseases (9%), shiga toxin due to
conclusionsSecondary thrombotic microangiopathies represent the majority of thrombotic microangiopathies. Multiple thrombotic microangiopathies causes are present in one half of secondary thrombotic microangiopathies. The risks of dialysis, neurologic and cardiac complications, and death vary by the cause of thrombotic microangiopathies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.